PMID- 40975475
OWN - NLM
STAT- Publisher
LR  - 20250923
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 1006
DP  - 2025 Sep 18
TI  - Transcriptomic profiling unveils novel therapeutic options for drug-resistant 
      temporal lobe epilepsy.
PG  - 178146
LID - S0014-2999(25)00900-8 [pii]
LID - 10.1016/j.ejphar.2025.178146 [doi]
AB  - BACKGROUND: Epilepsy drug treatments fail in 25-30 % of patients, leading to drug 
      resistance. Temporal lobe epilepsy is the most prevalent subtype associated with 
      drug resistance. Classical drug discovery is a long and extremely costly process 
      with a high failure rate in clinical trials. Drug repurposing is a more cost- and 
      time-effective strategy. Hence, the main objective of this study is to propose 
      drug candidates for the treatment of drug-resistant temporal lobe epilepsy 
      (DR-TLE) through drug repurposing based on transcriptomic profiling. METHODS: 
      Total RNA-sequencing (RNA-Seq) was performed on 45 formalin-fixed 
      paraffin-embedded (FFPE) hippocampi of DR-TLE patients and 36 FFPE hippocampi of 
      post-mortem biobank donors. RNA-Seq was carried out on an Illumina NovaSeq 6000 
      platform in 100bp paired-end. Drug repurposing based on transcriptomic analysis 
      top candidates was performed against these databases: Pandrugs2, PharmOmics, 
      DGIdb, ToppGene, L1000CDS(2) and Connectivity Map. RESULTS: We identified 887 
      genes differentially expressed between DR-TLE patients and post-mortem controls. 
      We observed 74 potential drug candidates in at least two independent databases. 
      Of these, we selected only the 11 which can cross the blood-brain barrier: 
      cobimetinib, panobinostat, melphalan, rucaparib, alectinib, ponatinib, danazol, 
      carboplatin, vandetanib, erlotinib, and gefitinib. After analyzing their 
      mechanisms to modulate epileptogenesis, their safety and efficacy profiles from 
      previous publications, we provide a list of the top 5 candidates. CONCLUSION: 
      Based on differential RNA-Seq profiling, we therefore propose erlotinib, danazol, 
      rucaparib, ponatinib, and panobinostat.
CI  - Copyright © 2025 Elsevier B.V. All rights reserved.
FAU - Sánchez-Jiménez, Patricia
AU  - Sánchez-Jiménez P
AD  - Clinical Pharmacology Department, Hospital Universitario de La Princesa, 
      Instituto de Investigaciones Sanitarias la Princesa (IIS-IP), Universidad 
      Autónoma de Madrid, Madrid, Spain; NIMGenetics Genómica y Medicina S.L., Madrid, 
      Spain.
FAU - Alonso-Guirado, Lola
AU  - Alonso-Guirado L
AD  - Genetic & Molecular Epidemiology Group, Spanish National Cancer Research Center 
      (CNIO), Madrid, Spain.
FAU - Cerrada-Gálvez, Laura
AU  - Cerrada-Gálvez L
AD  - Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, 
      Universidad San Pablo-CEU, CEU Universities, Spain.
FAU - Elizalde-Horcada, Marcos
AU  - Elizalde-Horcada M
AD  - Institut d'Investigació Sanitària Pere Virgili (IISPV), Bioinformatics Platform, 
      Reus, Tarragona, Spain.
FAU - Granero-Cremades, Inmaculada
AU  - Granero-Cremades I
AD  - Clinical Analysis Department, Hospital Universitario de La Princesa, Madrid, 
      Spain.
FAU - Maietta, Paolo
AU  - Maietta P
AD  - GenomCore S.L., Barcelona, Spain.
FAU - Gómez-Martín, Antonio
AU  - Gómez-Martín A
AD  - Andalusian School of Public Health (EASP), Granada, Spain; Instituto de 
      Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
FAU - Abad-Santos, Francisco
AU  - Abad-Santos F
AD  - Clinical Pharmacology Department, Hospital Universitario de La Princesa, 
      Instituto de Investigaciones Sanitarias la Princesa (IIS-IP), Universidad 
      Autónoma de Madrid, Madrid, Spain.
FAU - Torres-Díaz, Cristina Virginia
AU  - Torres-Díaz CV
AD  - Neurosurgery Department, Hospital Universitario de La Princesa, Madrid, Spain.
FAU - de Toledo, Maria
AU  - de Toledo M
AD  - Neurology Deparment, Hospital Universitario de La Princesa, Madrid, Spain.
FAU - Frade-Porto, Natalia
AU  - Frade-Porto N
AD  - Hospital Central de la Defensa "Gómez Ulla"., Madrid, Spain.
FAU - Gonzalez-Tarno, Patricia
AU  - Gonzalez-Tarno P
AD  - Neurosurgery Department, Hospital Universitario de La Princesa, Madrid, Spain.
FAU - Pulido, Paloma
AU  - Pulido P
AD  - Neurosurgery Department, Hospital Universitario de La Princesa, Madrid, Spain.
FAU - Ovejero-Benito, María C
AU  - Ovejero-Benito MC
AD  - Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, 
      Universidad San Pablo-CEU, CEU Universities, Spain. Electronic address: 
      maria.ovejerobenito@ceu.es.
LA  - eng
PT  - Journal Article
DEP - 20250918
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
SB  - IM
OTO - NOTNLM
OT  - Drug discovery
OT  - Drug repurposing
OT  - Drug-resistant epilepsy
OT  - RNA-Seq
OT  - Refractory epilepsy
OT  - Transcriptomics
COIS- Declaration of competing interest F Abad-Santos has been a consultant or 
      investigator in clinical trials sponsored by the following pharmaceutical 
      companies: Abbott, Alter, aptaTargerts, Chemo, Farmalíder, Ferrer, 
      GlaxoSmithKline, Gilead, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva, 
      and Zambon. MC Ovejero-Benito has potential conflicts of interest (research 
      support) with Leo Pharma. None of the conflicts of interest disclosed relate to 
      this publication. The rest of the authors have no relevant financial or 
      non-financial interests to disclose.
EDAT- 2025/09/21 00:29
MHDA- 2025/09/21 00:29
CRDT- 2025/09/20 19:42
PHST- 2024/11/04 00:00 [received]
PHST- 2025/09/08 00:00 [revised]
PHST- 2025/09/11 00:00 [accepted]
PHST- 2025/09/21 00:29 [pubmed]
PHST- 2025/09/21 00:29 [medline]
PHST- 2025/09/20 19:42 [entrez]
AID - S0014-2999(25)00900-8 [pii]
AID - 10.1016/j.ejphar.2025.178146 [doi]
PST - aheadofprint
SO  - Eur J Pharmacol. 2025 Sep 18;1006:178146. doi: 10.1016/j.ejphar.2025.178146.
